COVID-19: Status Report of “Avigan”: Japanese Society of Infectious Diseases
COVID-19:
April 18, 2020 19:27
Japanese Society of Infectious Diseases:
The Japanese Society for Infectious Diseases held a symposium on the 18th in Tokyo in order to prevent infections by delivering lectures without viewers on the Internet.
Members of the New Coronavirus Countermeasures / Government Experts Meeting, treating doctors, etc. reported the situation.
“The cases where COVID-19 patients were treated and the influenza / asthma medications improved were reported.”
Fujita Medical University:
Prof. Yohei Doi reported on the situation of administering the influenza drug “Avigan” to patients.
“Avigan”:
Of the 300 people who received Avigan,
Approximately 90% improvement in mild / moderate patients,
Approximately 60% improvement in critically ill patients requiring mechanical ventilation
After 2 weeks, the symptoms improved.
Professor Doi showed that the current clinical trials require further confirmation of the effects.
“Alvesco”:
Alvesco, a remedy for inhaled asthma, was also reported.
Of the 75 people who were given pneumonia,
3 people: Patients whose condition deteriorates and need a ventilator,
2 people: Patients who died,
It is possible to reduce the rate of deterioration compared to when this drug is not used.
“Medical collapse”: the role of prevention
Aichi Medical University / Tsuneo Morishima is a visiting professor who is involved in clinical research of administering the asthma drug “Alvesco” to patients.
This data alone is not enough to say yet.
Alvesco administration may “reduce the number of patients who have severe pneumonia and need a ventilator”.
NHK news
https://www.google.co.jp/amp/s/www3.nhk.or.jp/news/html/20200418/amp/k10012394661000.html